Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Gains from Sales and Divestitures (2017 - 2022)

Historic Gains from Sales and Divestitures for Usana Health Sciences (USNA) over the last 6 years, with Q1 2022 value amounting to $131000.0.

  • Usana Health Sciences' Gains from Sales and Divestitures rose 2596.15% to $131000.0 in Q1 2022 from the same period last year, while for Jan 2022 it was $131000.0, marking a year-over-year increase of 2596.15%. This contributed to the annual value of $131000.0 for FY2022, which is 2596.15% up from last year.
  • Per Usana Health Sciences' latest filing, its Gains from Sales and Divestitures stood at $131000.0 for Q1 2022, which was up 2596.15% from $104000.0 recorded in Q1 2021.
  • Usana Health Sciences' Gains from Sales and Divestitures' 5-year high stood at $131000.0 during Q1 2022, with a 5-year trough of $25000.0 in Q4 2018.
  • For the 4-year period, Usana Health Sciences' Gains from Sales and Divestitures averaged around $79750.0, with its median value being $81500.0 (2019).
  • As far as peak fluctuations go, Usana Health Sciences' Gains from Sales and Divestitures soared by 15000.0% in 2018, and later surged by 2596.15% in 2022.
  • Quarter analysis of 4 years shows Usana Health Sciences' Gains from Sales and Divestitures stood at $25000.0 in 2018, then skyrocketed by 136.0% to $59000.0 in 2019, then skyrocketed by 76.27% to $104000.0 in 2021, then rose by 25.96% to $131000.0 in 2022.
  • Its last three reported values are $131000.0 in Q1 2022, $104000.0 for Q1 2021, and $59000.0 during Q4 2019.